<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144855</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3474-I-01</org_study_id>
    <nct_id>NCT04144855</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection</brief_title>
  <official_title>A Phase I, Open-label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended
      dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3474 in
      patients with advanced malignant tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>Subjects appear the following toxic reaction relate to the drug after treatment within 28 days ：III °or above of non-hematological toxicity, IV° hematological toxicity , III ° neutropenia associated with fever, III ° thrombocytopenia with bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>0hour, 0.5hour, end of infusion, 5minutes, 15minutes, 0.5hour, 1hour, 2hour, 4hour, 7hour, 12hour, 24hour, 48hour, 144hour after infusion of day 1 and day 22; Hour 0, end of infusion of day 8 and day 15, hour 0 of day 29.</time_frame>
    <description>Cmax is the maximum plasma concentration of TQB3474 or metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0hour, 0.5hour, end of infusion, 5minutes, 15minutes, 0.5hour, 1hour, 2hour, 4hour, 7hour, 12hour, 24hour, 48hour, 144hour after infusion of day 1 and day 22; Hour 0, end of infusion of day 8 and day 15, hour 0 of day 29.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3474 by assessment of time to reach maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0hour, 0.5hour, end of infusion, 5minutes, 15minutes, 0.5hour, 1hour, 2hour, 4hour, 7hour, 12hour, 24hour, 48hour, 144hour after infusion of day 1 and day 22; Hour 0, end of infusion of day 8 and day 15, hour 0 of day 29.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3474 by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>TQB3474 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive TQB3474 injection by intravenous (IV) infusion on Day 1, 8, 15, 22 of each 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3474 injection</intervention_name>
    <description>This is a kind of heat shock protein (HSP90) inhibitor.</description>
    <arm_group_label>TQB3474 injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18 and 70 years old.

        2. Histologically or cytologically confirmed advanced solid tumors.

        3. Has the surgery more than 4 weeks before the first dose.

        4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.

        5. Life expectancy ≥12 weeks.

        6. Adequate organ system function.

        7. Male or female subjects should agree to use an adequate method of contraception starting
        with the first dose of study therapy through 6 months after the last dose of study.

        8. Understood and signed an informed consent form.

        Exclusion Criteria:

          1. Has received chemotherapy or radiotherapy within 4 weeks before the first dose.

          2. Hypersensitivity to TQB3474 or its excipient.

          3. Has factors that impact on intravenous infusion of drugs and venous blood collection.

          4. Has severe gastrointestinal disease within 4 weeks before the first dose.

          5. Has severe eye disease.

          6. Breastfeeding or pregnant women.

          7. Has brain metastases.

          8. HCV antibody and HCV-RNA positive; Syphilis positive; HBsAg positive and HBV DNA
             positive (≥1000 copies /mL).

          9. Has infection that need systemic treatment during screening.

         10. Has participated in any other clinical trial within 4 weeks before the first dose.

         11. According to the judgement of the researchers, there are other factors that subjects
             are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongsheng Wang, Doctor</last_name>
    <phone>028-85422707</phone>
    <email>licdzk@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weiqi Nian, Doctor</last_name>
      <phone>023-65079277</phone>
      <email>nwqone@126.com</email>
    </contact>
    <investigator>
      <last_name>Weiqi Nian, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guizhou Cancer Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weiwei Ouyang, Doctor</last_name>
      <phone>0851-86523929</phone>
      <email>Ouyangww103173@163.com</email>
    </contact>
    <investigator>
      <last_name>Weiwei Ouyang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yongsheng</name>
      <address>
        <city>Chendu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongsheng Wang, Doctor</last_name>
      <phone>028-85422707</phone>
      <email>licdzk@163.com</email>
    </contact>
    <investigator>
      <last_name>Yongsheng Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Zheng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

